We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Portable Monitor Detects Acute Respiratory Distress Syndrome

By LabMedica International staff writers
Posted on 22 Aug 2019
Print article
Image: Rapid breath analysis for acute respiratory distress syndrome diagnostics using a portable two-dimensional gas chromatography device (Photo courtesy of University of Michigan).
Image: Rapid breath analysis for acute respiratory distress syndrome diagnostics using a portable two-dimensional gas chromatography device (Photo courtesy of University of Michigan).
Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury, responsible for high mortality and long-term morbidity. As a dynamic syndrome with multiple etiologies, its timely diagnosis is difficult as is tracking the course of the syndrome.

Therefore, there is a significant need for early, rapid detection and diagnosis as well as clinical trajectory monitoring of ARDS. Timely diagnosis and tracking of ARDS are very challenging because the condition can alter and progress rapidly and has several possible causes.

Scientists at the University of Michigan (Ann Arbor, MI, USA) have developed a portable breath analyzer that can accurately and rapidly detect ARDS. The device promises to increase rates of survival and reduce healthcare costs for people with the potentially life threatening lung condition. They tested the technology on 48 volunteers who were receiving treatment at the University of Michigan hospital. Of the volunteers, 21 had ARDS and the others served as controls.

The device designed by the team was a fully automated portable two-dimensional gas chromatography device with high peak capacity (> 200 at the resolution of 1), high sensitivity (sub-ppb), rapid analysis capability (~ 30 minutes) and made in-house for on-site analysis of patients’ breath. The technology in the device uses gas chromatography to analyze nearly 100 molecules in exhaled breath. It captures a sample of breath through a tube that connects to a mechanical ventilator's exhalation port.

An algorithm based on machine learning, principal component analysis (PCA), and linear discriminant analysis (LDA) was developed. As compared to the adjudications done by physicians based on the Berlin criteria, the device and algorithm achieved an overall accuracy of 87.1% with 94.1% positive predictive value and 82.4% negative predictive value. The results of the analysis allowed doctors not only to test for ARDS but also to determine how far advanced the condition is. The device can also monitor treatment progress after diagnosis.

The scientists concluded that the high overall accuracy and high positive predicative value suggest that the breath analysis method can accurately diagnose ARDS. The ability to continuously and non-invasively monitor exhaled breath for early diagnosis, disease trajectory tracking, and outcome prediction monitoring of ARDS may have a significant impact on changing practice and improving patient outcomes. The study was published on August 1, 2019, in the journal Analytical and Bioanalytical Chemistry.

Related Links:
University of Michigan

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.